2 recruiting, 1 active not recruiting, 1 terminated. 1 Phase 1, 1 Phase 2, 1 Phase 3, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Active not recruiting 1 |
| Phase 2 | 1 | Active not recruiting 1 |
| Phase 3 | 1 | Terminated 1 |
| Phase 4 | 1 | Recruiting 1 |
Follow AChR Myasthenia Gravis: new trials by email Literature Review of AChR Myasthenia Gravis trials Research Report on AChR Myasthenia Gravis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| AXIS MG Patient Registry Myasthenia Gravis (MG), Myasthenia Gravis, Generalized | Recruiting | Autoimmune Neurology Alliance | 1000 | 2026-03-19 | 2026-08-17 | |
| Treatment of Myasthenia Gravis Exacerbation or Crisis With Efgartigimod Efgartigimod - Myasthenia Gravis Crisis, Myasthenia Gravis Exacerbations | Phase 4 | Recruiting | University of Colorado, Denver | 20 | 2025-03-06 | 2025-07-11 |
| Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects With Myasthenia Gravis CNP-106, Placebo - Myasthenia Gravis, Generalized Myasthenia | Phase 1 / Phase 2 | Active not recruiting | COUR Pharmaceutical Development Company, Inc. | 54 | 2024-05-30 | 2026-06-09 |
| Long Term Safety Study of Amifampridine Phosphate in MuSK-MG (Muscle Specific Tyrosine Kinase Myasthenia Gravis) Amifampridine Phosphate - Myasthenia Gravis, MuSK, AChR Myasthenia Gravis | Phase 3 | Terminated | Catalyst Pharmaceuticals, Inc. | 63 | 2018-06-11 | 2024-05-07 |
Myasthenia Gravis (3) · Autoimmune Diseases of the Nervous System (1) · Disease Progression (1) · Medication Adherence (1) · Neuromuscular Junction Diseases (1)
Autoimmune Diseases (3) · Immune System Diseases (3) · Neoplasms (3) · Neoplasms by Site (3) · Nervous System Diseases (3) · Nervous System Neoplasms (3) · Neurodegenerative Diseases (3) · Neuromuscular Diseases (3) · Paraneoplastic Syndromes (3) · Paraneoplastic Syndromes, Nervous System (3) · Autoimmune Diseases of the Nervous System (2) · Neuromuscular Junction Diseases (2) · Behavior (1) · Disease Attributes (1) · Health Behavior (1)
Amifampridine (1) · efgartigimod alfa (1)
Autoimmune Neurology Alliance (1) · COUR Pharmaceutical Development Company, Inc. (1) · Catalyst Pharmaceuticals, Inc. (1) · University of Colorado, Denver (1)
United States (4) · Italy (1)
Gary R Cutter, PhD (1) · Jared R Adams, MD, PhD (1) · Neelam Goyal, MD (1) · Paul Peloso, MD (1) · Renato Mantegazza, MD (1) · Richard J Nowak, MD, MS (1) · Srikanth Muppidi, MD (1) · Thomas Ragole, MD (1)